Company intelligence / Profile preview

Promatix Biosciences

London, England, United Kingdompro-matix.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Promatix is developing a pipeline of novel bispecific antibody-drug conjugates, exemplified by preclinical assets in colorectal cancer. The company leverages its TxPro platform to identify new target combinations that improve tumor selectivity and reduce off-tumor toxicity. No clinical results have been published as of May 2025.

Therapeutic areas: Oncology
Modalities: Bispecific antibodies (including cis-bispecific ADCs)Antibody Drug Conjugates (ADCs)
Industry: Biotech

Drug pipeline

2 assets

PBS293

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

ALSA Ventures — seed funding/incubation partner, academic collaborations mentioned but not named specifically.

Beyond the preview

Go deeper on Promatix Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Promatix Biosciences.

Explore the full profile